Case report: Response to ipilimumab in a patient with HIV with metastatic melanoma

Journal of Clinical Oncology

Volumn 29, Issue 32, 2011, Pages

  Burke, Matthew M ^a   Kluger, Harriet M ^b   Golden, Marjorie ^c   Heller, Kevin N ^d   Hoos, Axel ^d   Sznol, Mario ^b  

^a Smilow Cancer Hospital at Yale New Haven   (United States)

^b YALE CANCER CENTER   (United States)

^c HOSPITAL OF SAINT RAPHAEL   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; IPILIMUMAB; RITONAVIR;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MALE; MEDICAL HISTORY; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; MALE; MELANOMA; MIDDLE AGED; VIRAL LOAD;

EID: 81155123164     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.9199     Document Type: Article

References (15)

1. Patel P, Hanson DL, Sullivan PS, et al.: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148:728-736, 2008 (Pubitemid 351717418)
2. Hoffmann C, Horst HA, Weichenthal M, et al.: Malignant melanoma and HIV infection: Aggressive course despite immune reconstitution. Onkologie 28:35-37, 2005
3. Rodrigues LK, Klencke BJ, Vin-Christian K, et al.: Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 138:765-770, 2002 (Pubitemid 34625521)
4. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
5. Korman AJ, Peggs KS, Allison JP: Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339, 2006 (Pubitemid 43765802)
6. Peggs KS, Quezada SA, Chambers CA, et al.: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717-1725, 2009
7. Kaufmann DE, Walker BD: PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 182:5891-5897, 2009
8. Kaufmann DE, Kavanagh DG, Pereyra F, et al.: Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 8:1246-1254, 2007 (Pubitemid 350011764)
9. Riley JL, Schlienger K, Blair PJ, et al.: Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J Exp Med 191:1987-1997, 2000 (Pubitemid 30390360)
10. Cecchinato V, Tryniszewska E, Ma ZM, et al.: Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol 180:5439-5447, 2008
11. Hryniewicz A, Boasso A, Edghill-Smith Y, et al.: CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 108:3834-3842, 2006 (Pubitemid 44864566)
12. Morse CG, Mican JM, Jones EC, et al.: The incidence and natural history of osteonecrosis in HIV-infected adults. Clin Infect Dis 44:739-748, 2007
13. Brown P, Crane L: Avascular necrosis of bone in patients with human immunodeficiency virus infection: Report of 6 cases and review of the literature. Clin Infect Dis 32:1221-1226, 2001 (Pubitemid 32381126)
14. Finnefrock AC, Tang A, Li F, et al.: PD-1 blockade in rhesus macaques: Impact on chronic infection and prophylactic vaccination. J Immunol 182:980-987, 2009
15. Sznol M, Powderly JD, Smith DC, et al.: Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 28:205s, 2010 (suppl; abstr 2506)